Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis - Contacts and Locations

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

This study is currently recruiting participants.
Information provided by Cephalon

Please refer to this study by its ClinicalTrials.gov identifier: NCT00586651

Contacts


Contact: Cephalon Contact	1-800-283-4396

Locations


United States, Maryland
	Johns Hopkins University	Recruiting
	Baltimore, Maryland, United States, 21231
	Contact: Cedron Williams
	Principal Investigator: Alison Moliterno, MD

United States, New York
	NY Presbyterian-Cornell	Recruiting
	New York City, New York, United States, 10021
	Contact: Diane Lancaster, RN
	Principal Investigator: Gail Roboz, MD

United States, Pennsylvania
	University of Pennsylvania	Recruiting
	Philadelphia, Pennsylvania, United States, 19104
	Principal Investigator: Selina Luger, MD

Sponsors and Collaborators

Cephalon